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Abstract 
The development of a vaccine to prevent the contraction of the high-risk strands of human 
papillomavirus (HPV) 6, 11, 16 and 18 has the potential to prevent 70% of all cervical cancers. 
The Center for Disease Control and Prevention (CDC) currently recommends that girls aged 11-
12 receive the HPV vaccine.  At present, eighteen states have already decided or are considering 
to make HPV vaccination mandatory for adolescent girls.  As the HPV vaccine becomes 
mandatory, the demand for the vaccine is expected to rise dramatically.  This increase in demand 
could make our nation vulnerable to interruptions in HPV vaccine production. If an interruption 
occurs, many adolescent girls and women could be at an unnecessary risk of acquiring HPV if 
they were to miss routine HPV immunizations.  One major factor in the prevention of HPV 
vaccine shortages is the creation of vaccine stockpiles by the CDC.  In this paper, mathematical 
models are used to determine and analyze stockpile levels sufficient to minimize the effects of a 
production interruption for the HPV vaccine.  The results indicate that the stockpile level is 
highly sensitive to the vaccine coverage rate and the duration of the production interruption.  To 
protect against a six month interruption in vaccine production, a stockpile of at least 3M is 
recommended. 
 
1.  Introduction and background 
The human papillomavirus (HPV) is an extremely widespread disease.  An estimated 6.2 million 
Americans get a new genital HPV infection every year, and approximately 20 million people are 
currently infected with HPV [1].  By the age of 50, at least 80% of women will have had an HPV 
infection [2].  HPV has been recognized as the sole cause of cervical cancer [3]. In 2006, an 
estimated 10,000 women in the United States were diagnosed with cervical cancer and nearly 
4,000 are expected to die from it [3]. Cervical cancer strikes nearly half a million women each 
year worldwide and claims a quarter of a million lives, making it the third most common cause 
of cancer-related deaths worldwide [3, 4, 5, 6].  
 
It is estimated that over 100 types of HPV exist. Of those 100 types, more than 30 types can be 
passed through sexual contact. Of these 30 types, some are referred to as “low-risk” strands 
because they rarely develop into cancer, while the other types are referred to as “high-risk” 
because these strands are more likely to lead to cervical cancer [3].  It is believed that high-risk 
types 16 and 18 cause approximately 70% of cervical cancers and strains 6 and 11 cause 90% of 
genital warts [2,7].  
 
At present, there is a single manufacturer of HPV vaccines.  In June, 2006, the FDA approved 
Gardasil, a vaccine for HPV, manufactured by Merck, to protect against the four high-risk stands 
of HPV (6, 11, 16, 18).  Trials for Gardisil showed nearly 100% efficacy against persistent HPV 
infections [8-11,12].  Gardasil requires three shots of equal dosage.  The first shot is 
administered during a visit to a doctor, the second shot two months after the first, and the third 
dose six months after the first.  All doses are recommended to be given within a one-year period.   
 
There is likely to be a second manufacturer for HPV vaccines.  Cervarix is an experimental HPV 
vaccine manufactured by GlaxoSmithKline, and it is currently being tested by the FDA. It is 
anticipated to receive FDA approval in late 2009 [13]. Like Gardasil, Cervarix requires three 
shots of equal dosage.  The Center for Disease Control and Prevention (CDC) recommends that 
all females aged 11-12 years be vaccinated against HPV and that females aged 13-26 years be 
offered the vaccine [2,14,15].  At present, eighteen states are requiring or considering requiring 
HPV vaccination [16].   
 
Since there is currently a single manufacturer of HPV vaccines and since demand has been 
dramatically rising, the system is vulnerable to interruptions in vaccine production.  In such an 
interruption, the manufacturer’s production is completely halted, with no new additional 
vaccines being produced.  Existing vaccines would be used for routing immunizations until the 
existing stockpiles run out, when a shortage is said to occur.  Vaccine shortages, including the 
recent Hepatitis A, Haemophilus influenzae type B (Hib), and Varicella vaccine shortage, are a 
real concern and periodically occur [17,18].  It is important that children follow the CDC 
recommended immunization schedule to prevent exposure to preventable diseases.  Interruptions 
in HPV vaccine production can put women at risk of acquiring HPV infections.  
 
To avoid possibilities of widespread vaccine shortages, the CDC maintains vaccine stockpiles for 
pediatric and adolescent vaccines.  These stockpiles were first developed by CDC in 1983, and 
can be used to counteract short-term production problems, which are likely to occur periodically 
[19]. The CDC maintains stockpiles for a number of childhood vaccines; for example, 6-month 
stockpiles of measles, mumps, rubella (MMR), varicella, and inactivated polio (IPV) vaccines 
[19]. CDC has also purchased partial stockpiles of hepatitis B, hepatitis A, pneumococcal 
conjugate (PCV), Haemophilus influenzae type b (Hib), hepatitis B, diphtheria, tetanus and 
acellular pertussis vaccines, a combination vaccine containing DTaP, IPV, and hepatitis B, 
rotavirus, and a combination vaccine containing hepatitis B and Hib [19].  The CDC realizes that 
shortages are a serious problem and plans on continuing to purchase those vaccines and others, 
including new and combination vaccines, for the stockpiles. 
 
Mathematical modeling has been used to predict the level of a vaccine stockpile necessary to 
minimize the effect on the public from a shortage.  Elsewhere, these models have been used to 
determine appropriate vaccine stockpile levels for the vaccines on the pediatric recommended 
immunization schedule [20,21].  In this paper, these existing mathematical models for analyzing 
vaccine stockpiles for pediatric vaccines are applied to HPV vaccines.  The analysis focuses on 
the sensitivity of the stockpiles with respect to the vaccine coverage rate (i.e., the fraction of girls 
aged 11-12 who receive all three doses of the HPV vaccine), since the vaccine coverage rate for 
adolescent vaccines is lower than that of pediatric vaccines, more states are requiring HPV 
vaccination (additional changes are anticipated), and estimates for the vaccination rates of girls 
and women against HPV are not currently available.  The results indicate that the stockpile level 
changes significantly, depending on the vaccine coverage rate and assumptions regarding the 
production interruption.  The analysis is performed to analyze whether stockpile levels are 
sufficient to absorb the impact of a vaccine production interruption and maintain low risk of a 
shortage under a variety of production interruption scenarios. 
 
This paper is organized as follows.  In Section 2, the mathematical models used in the analysis 
are summarized.  In Section 3, the models are applied to anticipated scenarios of HPV 
vaccination and potential interruptions in its supply.  Finally, concluding remarks are given in 
Section 4. 
 
2.  Methods: model overview  
The mathematical model to analyze HPV vaccine stockpiles is formulated as a stochastic 
inventory model to capture the relationship between a vaccine supply and demand when 
production is interrupted [20].  During a production interruption, the manufacturing of any new 
vaccines is suspended, and hence, no new vaccines are available, and vaccine stockpiles will be 
used until they run out.  This model can be used to analyze various vaccination stockpile levels 
to determine if they are adequate to cover the demand for HPV vaccination.  It is assumed that 
the production interruption lasts for a random amount of time and that production resumes at 
time t = 0.  Note that these models are not specific to the HPV vaccine; they can be applied to 
any pediatric or adolescent vaccine. 
 
The models take several input parameters: 
? D = the number of doses required to provide full immunization. 
? I = initial stockpile level. 
? λ = expected number of people (i.e., 11 year old girls) that require the vaccine. 
? σ = standard deviation of people who require the vaccine. 
? α = vaccine coverage rate (proportion of 11 year old girls who receive the vaccine). 
? T = random variable describing the duration (in days) of a vaccine production 
interruption. 
? T ~ NT(η, σT) = T is distributed as a truncated normal random variable with parameters η 
and σT. 
? T ~ Exp(η) = T is distributed as an exponential random variable with parameter 1/η  
? β = the ratio between the maximum vaccine production rate (βDλ) and the vaccine 
demand rate (Dλ), where β > 1. 
? tM = the time at which the vaccine production returns to its maximum rate. 
? tm = time the at which the expected vaccine supply level reaches its minimum. 
? t = 0 = time at which the production is restored 
 
Note that the last three parameters tM, tm, and t are relative to the time that production resumes 
(time t = 0).   
 
The function )(tu captures both the vaccine production rate and the vaccine distribution rate.  To 
capture both these scenarios, two possible functional forms for )(tu over time period [ ]Mt,0  are 
considered to define two possible vaccine supply ramp-up rate functions.  The ramp-up rate 
function is quantified as the supply rate moves from zero to its maximum production capacity. 
The convex and concave vaccine production ramp-up rate functions are given by  
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where r = 2 for the convex ramp-up rate function and r = ½ for the concave ramp-up rate 
function.  
 
During an interruption in vaccine production and during ramp-up phase, there is a probability 
that the vaccine supply is entirely used, resulting in a vaccine shortage.  This means that the 
demand cannot be met, and therefore the need for the vaccine is actually greater than the supply, 
so in essence, the supply becomes negative.  The expected accumulated vaccine supply shortage 
δ(tm) during time interval [ ]Mt,0  is given by  
( ) ( ) ( )[ ] mtmmm tDdttutDEtGt m αλδ −=−= ∫0 )(,0,0     (3)  
where G(0, tm) and D denote the (deterministic) cumulative production demand and the (random variable) 
cumulative demand over time interval [0, +tm], respectively.  Let S(tm) denote the supply at the time at 
which the expected vaccine supply level reaches its minimum.  The expected minimum vaccine 
supply E[S(tm)] is given by 
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Note that in (3) and (4), ( )mtδ  depends only on how fast the manufacturer can achieve its 
maximum production rate, and that ( )mtδ  is neither a function of the initial stockpile level nor the 
length of the actual production interruption period.   
 
The probability of a shortage during a vaccine production interruption is estimated by  
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In (9), the formula is an approximation, and the symbols ( ≥≤, ) should not be considered exact.  
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Since the exact distribution of T is unknown, two distinct distributions were considered. Both 
distributions have parameters that could be varied to control the coefficient of variation for T.  
The first distribution is the truncated normal with parameters η  and Tσ , and its probability 
distribution function for T is given by 
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The second distribution considered is the exponential distribution with parameter 1/η.  The 
exponential distribution for T has a higher coefficient variation, and hence, it models the scenario 
when the length of the production interruption is highly uncertain.  The probability density 
function for an exponential distribution with parameter 1/η is given by 
 ηη
T
eTf
−= 1)( .         (6) 
Note that the truncated normal and the exponential distributions are two particular probability 
density functions that can be used to model the length of the production interruption and that any 
probability density functions can be used in the models introduced in this section. 
3.  Results 
 
This section provides an analysis of the vaccine stockpile models provided using parameters for 
the HPV vaccine using the models introduced in Section 2.  Specific parameters and distributions 
for the HPV vaccine are provided in order to analyze stockpile levels under a wide variety of 
assumptions regarding the vaccine production interruption. 
? T ~ NT(η, σT).  T is distributed as a truncated normal random variable with parameters 
NT(60, 10), NT(60, 20), NT(120, 20), NT(120, 40), NT(180, 30), NT(180, 60). 
? T ~ Exp(η).  T is distributed as an exponential random variable with parameter 1/η = {60, 
120, 180}  
 
In addition, two scenarios are considered with an expected production interruption of six months. 
? Optimistic Scenario has parameters T ~ NT(η =180, σT = 60), tM = 60, and a concave 
ramp-up function. 
? Pessimistic Scenario has parameters T ~ NT(η =180, σT = 30), tM = 180, and a convex 
ramp-up function. 
 
Depending on the scenario used, and the distribution specified, the vaccine stockpile changed 
significantly.  Based on only girls aged 11 years receiving vaccinations, λ = 5500 and σd = 950 
[23, 24].  The models were analyzed using Mathematica 5.2 and Matlab 6. 
 
Table 1 shows the minimum initial stockpiles levels of the HPV vaccine in order to maintain less 
than a ten-percent risk of a shortage under various scenarios.  Depending on the vaccine 
coverage rate (α) and the type of scenario considered, the stockpile levels change significantly, 
varying between 2.175M and 8.775M.  The cost is determined by multiplying the CDC cost per 
dose ($96.75) by the given initial stockpile levels.  Note that the stockpile increases linearly with 
the vaccine coverage rate.  As the vaccine coverage rate increases by ten-percent for the 
optimistic case, it is recommended that the corresponding stockpile increases by 475K and 730K 
for the truncated normal and exponential scenarios.  As the vaccine coverage rate increases by 
ten-percent for the pessimistic case, it is recommended that the corresponding stockpile increases 
by 605K and 935K for the truncated normal and exponential scenarios. 
 
 
Table 1:  Minimum stockpile level such that P(tm) < 0.1 (Millions of doses) and its corresponding 
cost ($M) 
 Optimistic Case  Pessimistic Case 
  Truncated Normal Exponential Truncated Normal Exponential 
α Stockpile(M) Cost($M) Stockpile(M) Cost($M) Stockpile(M) Cost($M) Stockpile(M) Cost($M) 
0.5 2.175 210 3.475 336 2.5 242 4.1 397 
0.6 2.625 254 4.175 404 3.075 298 5 484 
 
 
Table 2 shows upper bound for the expected minimum vaccine supply for the convex and 
concave scenarios given the average duration of the production interruption and the vaccine 
coverage rate.  Problems in HPV vaccine delivery occur when the expected vaccine supply is 
less than zero.  For this reason, the negative values in Table 2 are denoted in bold.  When the 
initial stockpile is 2M, depleting the vaccine supply is likely, even for some scenarios when the 
duration of the production interruption is 60 days.  When the initial stockpile is 3M, the vaccine 
supply becomes negative for expected production interruptions of 120 days (α ≥ 0.9) and 180 
days (α ≥ 0.7).  The vaccine supply is not expected to be depleted for any scenarios when the 
initial stockpile level is at least 5M. 
 
Table 2: Upper bound for the expected minimum vaccine supply, E[S(tm)] (Millions of doses) 
    I = 2M I = 3M I = 4M I = 5M I = 6M 
η α concave convex concave convex concave convex concave convex concave convex 
60 0.5 1.40 0.84 2.40 1.84 3.40 2.84 4.40 3.84 5.40 4.84 
60 0.6 1.23 0.53 2.23 1.53 3.23 2.53 4.23 3.53 5.23 4.53 
60 0.7 1.03 0.20 2.03 1.20 3.03 2.20 4.03 3.20 5.03 4.20 
60 0.8 0.79 -0.14 1.79 0.86 2.79 1.86 3.79 2.86 4.79 3.86 
60 0.9 0.51 -0.50 1.51 0.50 2.51 1.50 3.51 2.50 4.51 3.50 
60 1 0.19 -0.88 1.19 0.12 2.19 1.12 3.19 2.12 4.19 3.12 
120 0.5 0.91 0.34 1.91 1.34 2.91 2.34 3.91 3.34 4.91 4.34 
120 0.6 0.64 -0.07 1.64 0.93 2.64 1.93 3.64 2.93 4.64 3.93 
120 0.7 0.33 -0.49 1.33 0.51 2.33 1.51 3.33 2.51 4.33 3.51 
120 0.8 0.00 -0.93 1.00 0.07 2.00 1.07 3.00 2.07 4.00 3.07 
120 0.9 -0.38 -1.39 0.62 -0.39 1.62 0.61 2.62 1.61 3.62 2.61 
120 1 -0.80 -1.87 0.20 -0.87 1.20 0.13 2.20 1.13 3.20 2.13 
180 0.5 0.41 -0.15 1.41 0.85 2.41 1.85 3.41 2.85 4.41 3.85 
180 0.6 0.04 -0.66 1.04 0.34 2.04 1.34 3.04 2.34 4.04 3.34 
180 0.7 -0.36 -1.18 0.64 -0.18 1.64 0.82 2.64 1.82 3.64 2.82 
180 0.8 -0.79 -1.73 0.21 -0.73 1.21 0.27 2.21 1.27 3.21 2.27 
180 0.9 -1.27 -2.28 -0.27 -1.28 0.73 -0.28 1.73 0.72 2.73 1.72 
180 1 -1.79 -2.86 -0.79 -1.86 0.21 -0.86 1.21 0.14 2.21 1.14 
 
0.7 3.075 298 4.9 474 3.65 353 5.925 573 
0.8 3.55 343 5.625 544 4.275 414 6.85 663 
0.9 4.05 392 6.375 617 4.875 472 7.8 755 
1.0 4.55 440 7.125 689 5.525 535 8.775 849 
 
Figure 1 shows the probability of a shortage as a function of the initial stockpile level for 
pessimistic scenario with the duration of the production interruption being modeled with the 
truncated normal (NT) or the exponential (Exp) distributions for α = 0.5, 0.7, 0.9.  The truncated 
normal scenarios appear to be more sensitive to the initial stockpile level than the exponential 
scenarios.  However, all scenarios appear to be sensitive to the vaccine coverage rate.  This 
suggests that accurate forecasts of the vaccine coverage rate are needed to plan effectively for an 
initial stockpile.  In addition, the stockpile may need to be significantly increased as the vaccine 
coverage rate increases. 
 
Figure 1: Probability of a Vaccine Shortage with tM = 180 and a convex ramp-up function. 
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Tables 3 and 4 show the probability of a vaccine supply shortage for various scenarios 
considered.  An initial stockpile of 2M appears to be inadequate to prevent shortages for even 
low levels of the vaccine coverage rate.  An initial stockpile of 3M appears to be adequate for 
vaccine coverage levels less than 0.7, with the probabilities of a shortage being less than 0.136 
for all scenarios considered with the expected duration of the production interruption being 120 
days or less.  An initial stockpile of 3M has probabilities of a shortage being less than 0.20 for all 
scenarios considered with α ≤ 0.9 for the concave case and less than 0.75 for all scenarios 
considered with α ≤ 0.9 for the convex case. 
 
4.  Discussions and Recommendations 
The analysis performed indicates that a stockpile for the HPV vaccine can be a tool to avoid 
vaccine shortages when production interruptions occur.  The stockpile level recommended to 
ensure a small risk of a shortage is sensitive to changes in the vaccine coverage rate.  Therefore, 
the HPV vaccine stockpile level should be a function of the vaccine coverage rate, and the 
stockpile should grow as a higher proportion of adolescent girls are vaccinated. 
 
The demand for HPV vaccines is likely to increase, and when this happens, the stockpile for the 
vaccine will need to grow. To demonstrate the likelihood that the vaccine demand will increase, 
note that the recommended childhood immunization coverage rates for every vaccine are at an 
all-time high and that there have been significant increases in the childhood vaccine coverage 
rates.  For example, the vaccine coverage rate for some vaccines increased ten-percent between 
2004 and 2005.  In the year 2005, the coverage rates for three or more doses of the childhood 
pneumococcal conjugate vaccine was 83 percent [22].  The recommended stockpile level of at 
least 3M vaccines is only sufficient to meet demands consistent with vaccine coverage levels 
associated with other adolescent vaccines.  However, as more state and local school systems 
make the HPV vaccine mandatory, the vaccine coverage rate is anticipated to increase and the 
stockpile level necessary will need to increase accordingly.   
 
The analysis performed only took one manufacturer of the HPV vaccination into account. 
However, since Cervarix is likely to be approved by the FDA in the near future, the 
recommended results can be modified to account for a second manufacturer.  In addition, 
Cervarix is likely to increase the total number of women who choose to receive the HPV 
vaccine, since Cervarix is seeking approval to be used on women up to the age of 55 whereas 
Gardasil can be used for women up to the age of 26.  In order to analyze vaccine stockpiles under 
the scenario when there are two HPV vaccine manufacturers, the expected value and the standard 
deviation of people who require the vaccine may need to be adjusted in the model. 
 
The HPV vaccine is an important public health tool to prevent HPV infections and cervical 
cancer.   The models analyzed in this paper shed light on appropriate stockpile levels for the 
HPV vaccine.  By creating such a stockpile, adolescent girls and women can be protected from 
HPV if there is a vaccine shortage, and countless lives could be saved. 
 
Table 3:  Probability of a vaccine supply shortage, Concave case 
η σT  α  I = 2M I = 3M I = 4M I = 5M I = 6M 
      0.5   0 0 0 0 0 
    0.6  0 0 0 0 0 
    0.7  0 0 0 0 0 
  20  0.8  0.001591 0 0 0 0 
    0.9  0.044626 0 0 0 0 
60     1   0.291553 0.000159 0 0 0 
    0.5  0 0 0 0 0 
    0.6  0 0 0 0 0 
  10  0.7  0 0 0 0 0 
    0.8  0 0 0 0 0 
    0.9  0.000337 0 0 0 0 
      1   0.135666 0 0 0 0 
    0.5  0.002984 0 0 0 0 
    0.6  0.054873 1.86E-05 0 0 0 
  40  0.7  0.242291 0.002023 0 0 0 
    0.8  0.510662 0.030437 8.01E-05 0 0 
    0.9  0.743157 0.152888 0.003219 0 0 
120     1   0.890915 0.382605 0.035979 0.000443 0 
    0.5  0 0 0 0 0 
    0.6  0.000687 0 0 0 0 
  20  0.7  0.080757 0 0 0 0 
    0.8  0.519939 8.84E-05 0 0 0 
    0.9  0.9032 0.020182 0 0 0 
      1   0.992857 0.274253 0.000159 0 0 
    0.5  0.202602 0.002189 0 0 0 
    0.6  0.474063 0.040113 0.000299 0 0 
  60  0.7  0.704049 0.179902 0.008987 7.24E-05 0 
    0.8  0.846487 0.401836 0.064763 0.002694 2.75E-05 
    0.9  0.925368 0.625096 0.207339 0.026634 0.001084 
180     1   0.966671 0.78921 0.421309 0.112017 0.012781 
    0.5  0.04779 0 0 0 0 
    0.6  0.446965 0.000233 0 0 0 
  30  0.7  0.856939 0.033377 0 0 0 
    0.8  0.978991 0.308538 0.001209 0 0 
    0.9  0.997926 0.736742 0.0512 5.52E-05 0 
      1   0.99986 0.945201 0.344578 0.00748 0 
 
Table 4:  Probability of a vaccine supply shortage, Convex case 
 
η σT  α  I = 2M I = 3M I = 4M I = 5M I = 6M 
      0.5   0 0 0 0 0 
    0.6  0.00403 0 0 0 0 
    0.7  0.19793 0 0 0 0 
  20  0.8  0.709798 0.000578 0 0 0 
    0.9  0.956726 0.049538 0 0 0 
60     1   0.99788 0.36366 0.000337 0 0 
    0.5  0 0 0 0 0 
    0.6  0 0 0 0 0 
  10  0.7  0.044566 0 0 0 0 
    0.8  0.864334 0 0 0 0 
    0.9  0.999663 0.000483 0 0 0 
      1   1 0.241964 0 0 0 
    0.5  0.152888 2.56E-05 0 0 0 
    0.6  0.57023 0.009399 0 0 0 
  40  0.7  0.859974 0.135849 0.000578 0 0 
    0.8  0.963351 0.45087 0.022781 4.82E-05 0 
    0.9  0.991952 0.751176 0.15887 0.003472 0 
120     1   0.999163 0.908641 0.421309 0.044626 0.000746 
    0.5  0.020182 0 0 0 0 
    0.6  0.636831 0 0 0 0 
  20  0.7  0.984222 0.013903 0 0 0 
    0.8  0.999807 0.401294 3.17E-05 0 0 
    0.9  0.999999 0.911492 0.02275 0 0 
      1   1 0.995975 0.344578 0.000337 0 
    0.5  0.625096 0.044626 9.46E-05 0 0 
    0.6  0.869105 0.285856 0.012241 4.19E-05 0 
  60  0.7  0.958274 0.605955 0.121837 0.004446 2.79E-05 
    0.8  0.986826 0.82145 0.369941 0.054873 0.002204 
    0.9  0.996211 0.927723 0.631411 0.212142 0.028362 
180     1   0.999483 0.971484 0.808028 0.447569 0.128178 
    0.5  0.736742 0.000337 0 0 0 
    0.6  0.987237 0.128537 0 0 0 
  30  0.7  0.999702 0.703099 0.009815 0 0 
    0.8  0.999994 0.966623 0.252493 0.000687 0 
    0.9  1 0.998134 0.747507 0.054799 8.71E-05 
      1   1 0.999917 0.958482 0.394863 0.012596 
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